The final analysis of the DESTINY-Lung02 trial, a dose-blinded phase 2...
The VENUS study is a prospective translational single-institution study that...
Ubamatamab is a bispecific antibody targeting MUC16 on ovarian cancer cells and...
This poster presents findings from the Spectrum study, a single-center...
The ENGOT-cx12 inovaTV 301 trial, co-authored by Professor Vergote and by Prof...
In a subgroup population analysis from the DESTINY-Pan Tumor 02 study, the...
The data presented here is from a pre-planned analysis of the Flipper trial,...
This study explores the role of ctDNA in low estrogen receptor (ER) tumours,...
In this study, researchers focused on cyclin-E1 amplified breast cancer, found...
Dr Frederic Forget discusses in this poster AIPAC-003, a new study with...